SensoDetect AB recently completed a presentation at the Redeye Theme: Medtech & Diagnostics event, where CEO PA Hedin and Dr. Mohamed Hussein Atwa discussed the company's advancements and strategies in neuro-auditory screening. The presentation highlighted the challenges in traditional mental health assessments, such as ADHD and autism, which are often slow and subjective. SensoDetect offers a faster, objective solution through its BERA-based screening, which involves a brief auditory test and quick AI-driven analysis to assess risk levels. The company is transitioning from a niche diagnostic tool to a broader screening platform, targeting environments like schools and corporations. They have identified a significant market opportunity in the ADHD and autism sectors, which are valued at over USD 500 billion globally. SensoDetect's business model includes device sales, placements, and per-screening revenue, with AI improvements strengthening their competitive position. The presentation also covered strategic growth areas, including ADHD clinical support centers, school-based screening, and early childhood programs. SensoDetect's technology measures neural timing and brainstem connectivity, offering early detection of neurodevelopmental issues. SensoDetect is expanding into China and the MENA region, aligning with local policies and conducting large-scale pilots. The company aims to standardize its screening globally by 2028, with plans for a Neuro Status Index and integration into neonatal programs. CEO PA Hedin emphasized the company's mission to provide clarity for families and redefine mental health screening, while Dr. Atwa highlighted the shift from subjective observation to measurable brain data. For more information, interested parties can contact PA Hedin directly.

SensoDetect AB meddelar att VD PA Hedin och Dr. Mohamed Hussein Atwa, Global Head of Clinical Research, kommer att presentera vid Redeye Theme: Medtech & Diagnostics den 12 november 2025. Presentationen, som hålls på engelska, kommer att vara 12 minuter lång följt av en 8 minuters frågestund. Eventet är det tolfte årliga Redeye-eventet med fokus på Medtech & Diagnostics-sektorn och kommer att inledas med en marknadsintroduktion av Redeyes analytiker. Presentationer från utvalda företag kommer att följa, och investerare kommer att delta både på plats och via livestream. Tittare kan ställa frågor direkt via eventets sida, med frågestunden modererad av Redeyes analytikerteam. PA Hedin och Dr. Mohamed Hussein Atwa framhåller SensoDetects framsteg inom neuro-auditiv hjärnskanning och dess kliniska arbete som visar stark konsistens och tillämplighet. En inspelning av presentationen kommer att finnas tillgänglig på Redeyes plattform efter eventet. För mer information eller partnerskapsförfrågningar kan PA Hedin kontaktas.

SensoDetect AB will visit China from November 16–30, 2025, to advance their joint venture with Beijing Mind Exploration Medical Technology Co., Ltd. The delegation, including key company figures, aims to meet with clinical, regulatory, and industrial partners in Beijing and Shenzhen. The focus is on finalizing clinical pathways, advancing regulatory processes, and scaling up sales and marketing efforts. The trip's agenda includes clinical collaboration meetings, regulatory planning, and manufacturing reviews. The Q3 report release has been delayed to November 27 due to this trip.

A delegation from SensoDetect, including key figures such as Dr. Mohamed Hussein Atwa Ahmed, Ahmad Alosta, and Maher Almajzoub, discussed their updated market strategy, which involves two commercial models: Private School Screening Programs and SensoDetect-Owned Screening Centers. These initiatives aim to provide neuro-auditory screening for early identification of neurodevelopmental conditions. CEO PA Hedin highlighted growing regional interest in structured screening, which combines school programs with company-owned centers for better accessibility and long-term presence. An ongoing autism study led by Dr. Fatimah is progressing as planned, with upcoming data expected to enhance screening and referral processes. The SensoDetect BERA method is seen as aligning well with current educational and healthcare initiatives. The company is engaging with school networks to integrate structured screening into student health programs, and emphasizes local coordination for sustainable implementation. Further updates will follow as agreements are finalized.